Leaps by Bayer led a $90 million investment round into Ada, a German digital health startup with an AI-based symptom checker. As part of the deal, the two companies are also striking a broader strategic partnership.
BlueRock Therapeutics, a Bayer subsidiary, is teaming up with Opsis Therapeutics and Fujifilm Cellular Dynamics in an R&D pact focused on developing stem cell therapies for eye diseases. BlueRock is paying its new partners $30 million up front to kick off the alliance.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker's molecule library and Recursion's artificial intelligence-based drug discovery platform.
The company hopes to use the money to bring its T-cell antigen coupler cell therapy technology - currently in preclinical development - into human clinical trials. German drugmaker Bayer's venture capital arm led the round.
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.
According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.
Among 29 patients, the drug - designed for patients who become resistant to TRK inhibitors like Vitrakvi - showed a 34 percent response rate, according to Phase I data.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
A roundup of some of the biggest trends and events in pharmaceuticals, biotechnology and diagnostics in 2018, including regulatory approvals, international trends, national policy and more.
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
During a panel at MedCity INVEST, four experts addressed what VCs and potential acquirers are looking for in emerging companies.
Ahead of his participation in a breakout panel at MedCity INVEST in May, Bayer's U.S. head of digital innovation Dirk Schapeler discussed his role unique role finding and partnering with compatible digital companies around the world.
The German life sciences company plans to bring its accelerator program for digital health startups to San Francisco. It's now available in Berlin, Moscow, and Shanghai among other places.